Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor models for efficacy determination.

Beverly A Teicher1

  • 1Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701, USA. beverly.teicher@genzyme.com

Molecular Cancer Therapeutics
|October 17, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORS.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Endosialin (CD248) Cancer Role and Therapeutics: 33 Years on.

Molecular cancer therapeutics·2026
Same author

Lamin A/C loss promotes R-loop-mediated genomic instability and poor survival in small-cell lung cancer.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

High-throughput combination screening of Pidnarulex and other G-quadruplex ligands in multi-cell type tumor spheroids.

SLAS discovery : advancing life sciences R & D·2025
Same author

Lamin A/C Deficiency Drives Genomic Instability and Poor Survival in Small-Cell Lung Cancer through Increased R-loop Accumulation.

bioRxiv : the preprint server for biology·2025
Same author

RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types.

Cancer research communications·2025

Early mouse leukemia models, grown as ascites, allowed mathematical analysis similar to bacteria. Subsequent research developed diverse in vivo solid tumor models for drug discovery, each with unique pros and cons.

Area of Science:

  • Oncology
  • Pharmacology
  • Biomedical Research

Background:

  • The development of in vivo tumor models began in the mid-1960s with mouse leukemia ascites models.
  • These early models allowed mathematical analysis of tumor growth and drug response, similar to bacterial studies.

Purpose of the Study:

  • To review the evolution and variety of in vivo tumor models used in drug discovery.
  • To highlight the advantages and disadvantages of different models for identifying improved cancer treatments.

Main Methods:

  • Historical overview of in vivo tumor model development.
  • Categorization of current mouse tumor models, including syngeneic, xenograft, orthotopic, disseminated, labeled, and transgenic models.

Main Results:

Related Experiment Videos

  • Significant advancements have been made from early leukemia models to sophisticated solid tumor models.
  • A diverse array of in vivo models now exists, catering to various research needs in oncology drug development.

Conclusions:

  • The selection of an appropriate in vivo tumor model is critical for effective drug discovery.
  • Each model type presents specific benefits and limitations for researchers seeking novel cancer therapeutics.